GUANGZHOU, China, April 14, 2025 /PRNewswire/ -- Fangzhou Inc. (06086.HK), a leading Internet healthcare solution provider, made a notable appearance at the "AI Empowers Biopharma" exchange panel held on April 3, 2025. This event, hosted by the Guangzhou Development District Talent Education Group, brought together 28 enterprises to explore the transformative applications of artificial intelligence in healthcare.

During the panel, Guo Zhi, Senior Vice President of Technology at Fangzhou, shared insights into the company's pioneering AI + H2H Smart Healthcare Ecosystem. This innovative model tackles core challenges in healthcare delivery by extending crucial services, such as chronic disease management, patient education, and medication delivery, directly into patients' homes. According to Guo Zhi, this approach significantly improves care accessibility and timeliness while enhancing the overall treatment experience.

A key highlight of Fangzhou's presentation was the unveiling of its proprietary framework designed to mitigate AI hallucinations in medical applications. This framework combines a self-developed training platform with a professional medical knowledge base and a data sandbox. This unique combination powers Fangzhou's "AI Agent Matrix," which provides round-the-clock diagnostic support, intelligent customer service tools, and AI-assisted health content creation. The result is improved care accessibility and reduced operational costs.

Fangzhou has articulated a clear blueprint for vertical AI leadership. The company plans to intensify its focus on the AI + Healthcare vertical, leveraging its proven H2H Smart Healthcare Ecosystem to drive deeper integration of AI across online healthcare use cases. Fangzhou aims to strengthen collaboration with biopharmaceutical enterprises and research institutions, fostering synergistic development between regional biomedicine and smart healthcare.

The company's AI-powered growth strategy centers on deploying cutting-edge AI technologies like DeepSeek-V3 while deepening partnerships with industry leaders such as Tencent Health and Tencent Cloud. These initiatives are designed to push the boundaries of AI-powered healthcare, strengthen Fangzhou's technological leadership, and fast-track the market adoption of its innovations, all with the overarching goal of delivering superior care experiences and enhanced solutions for patients and users.

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) stands as China's leading online chronic disease management platform, boasting 49.2 million registered users and a network of 223,000 physicians as of December 31, 2024. The company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com.

About the "AI Empowers Biopharma" Exchange Panel

The Guangzhou Development District is actively accelerating its push to become a biopharma innovation leader. The "AI Empowers Biopharma" exchange panel spotlights AI-driven antibody research, quantum computing for drug development, and smart healthcare ecosystems.

Media Contact

For further inquiries or interviews, please contact:

Xingwei Zhao Associate Director of Public Relations Email: [email protected]

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.